New Frontiers in Pancreatic Cancer Research

Surgical Oncology Clinics of North America

Volumn 19, Issue 2, 2010, Pages 431-451

  Khan, Gazala N ^a   di Magliano, Marina Pasca ^a   Simeone, Diane M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Biomarkers; Cancer stem cells; Pancreatic cancer; Signaling pathways

Indexed keywords

BIOLOGICAL MARKER; CD24 ANTIGEN; CRE RECOMBINASE; HERMES ANTIGEN; PROTEIN P48; TRANSCRIPTION FACTOR PDX 1; TUMOR ANTIGEN;

ALLELE; CANCER MODEL; CANCER MORTALITY; CANCER RESEARCH; CANCER STEM CELL; CELL RENEWAL; DISEASE MARKER; EARLY DIAGNOSIS; GENE; GENE CASSETTE; GENE INSERTION; GENE REPRESSION; GENE SILENCING; GENOME ANALYSIS; HUMAN; INTRON; LETHALITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE K RAS; P48 GENE; PANCREAS ADENOCARCINOMA; PDX1 GENE; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 75849152925     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2009.11.010     Document Type: Review

References (101)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 2 (2008) 71-96
2. Trede M., Schwall G., and Saeger H.D. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 211 4 (1990) 447-458
3. Sultana A., Smith C.T., Cunningham D., et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25 18 (2007) 2607-2615
4. Sultana A., Tudur Smith C., Cunningham D., et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96 8 (2007) 1183-1190
5. Duffy M.J. CA19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 35 (1998) 364-370
6. Barugola G., Frulloni L., Salvia R., et al. Is CA 19-9 a screening marker?. Dig Liver Dis 41 5 (2009) 325-327
7. Audisio R.A., Veronesi P., Maisonneuve P., et al. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Surg Oncol 5 2 (1996) 49-63
8. Frebourg T., Bercoff E., Manchon N., et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 62 11 (1988) 2287-2290
9. Brichory F.M., Misek D.E., Yim A.M., et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 98 (2001) 9824-9829
10. Le Naour F., Misek D., Krause M., et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 7 (2001) 3328-3335
11. Stockert E., Jager E., Chen Y.T., et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187 (1998) 1349-1354
12. Raedle J., Oremek G., Welker M., et al. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 13 (1996) 241-246
13. Ben-Mahrez K., Sorokine I., Thierry D., et al. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 46 (1990) 35-38
14. Pupa S.M., Menard S., Andreola S., et al. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 53 (1993) 5864-5866
15. Hamanaka Y., Suehiro Y., Fukui M., et al. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103 (2003) 97-100
16. Maacke H., Hundertmark C., Miska S., et al. Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J Cancer Res Clin Oncol 128 (2002) 219-222
17. Xia Q., Kong X.T., Zhang G.A., et al. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun 330 (2005) 526-532
18. Kotera Y., Fontenot J.D., Pecher G., et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54 (1994) 2856-2860
19. Logsdon C.D., Simeone D.M., Binkley C., et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63 (2003) 2649-2657
20. Crnogorac-Jurcevic T., Efthimiou E., Nielsen T., et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21 (2002) 4587-4594
21. Simeone D.M., Ji B., Banerjee M., et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34 4 (2007) 436-443
22. Koopman J., Rosenzweig N.W., Zhang Z., et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus Ca 19-9. Clin Cancer Res 12 (2006) 442-446
23. Gold D.V., Modrak D.E., Ying Z., et al. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 24 (2006) 252-258
24. Misek D.E., Patwa T.H., Lubman D.M., et al. Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw 5 10 (2007) 1034-1041
25. Zhao J., Patwa T.H., Lubman D.M., et al. Protein biomarkers in cancer: natural glycoprotein microarray approaches. Curr Opin Mol Ther 10 6 (2008) 602-610
26. Zhao J., Patwa T.H., Qiu W., et al. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis, and pancreatic cancer sera. J Proteome Res 6 (2007) 1864-1874
27. Chen S., LaRoche T., Hamelinck D., et al. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 4 5 (2007) 437-444
28. Rhodes D.R., Yu J., Shanker K., et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6 1 (2004) 1-6
29. Yang Y., Pospisil P., Iyer L.K., et al. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer. PLoS One 3 11 (2008) e3661
30. Harsha H.C., Kandasamy K., Ranganathan P., et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6 4 (2009) e1000046
31. Dalton W.S., and Friend S.H. Cancer biomarkers-an invitation to the table. Science 312 (2006) 1165-1168
32. Gullo L., Pezzilli R., and Morselli-Labate A.M. Diabetes and the risk of pancreatic cancer. N Engl J Med 331 2 (1994) 81-84
33. Basso D., Brigato L., Veronesi A., et al. The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res 15 6B (1995) 2585-2588
34. Ogawa Y., Tanaka M., Inoue K., et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 94 9 (2002) 2344-2349
35. Damiano J., Bordier L., Le Berre J.P., et al. Should pancreas imaging be recommended in patients over 50 years when diabetes is discovered because of acute symptoms?. Diabetes Metab 30 2 (2004) 203-207
36. Basso D., Greco E., Fogar P., et al. Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause?. Clin Chim Acta 372 1-2 (2006) 120-128
37. Pfeffer F., Koczan D., Adam U., et al. Expression of connexin 26 in islets of langerhans is associated with impaired glucose tolerance in patients with pancreatic adenocarcinoma. Pancreas 29 (2004) 284-290
38. Bentwich I. Prediction and validation of microRNAs and their targets. FEBS Lett 579 26 (2005) 5904-5910
39. Bentwich I., Avniel A., Karov Y., et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37 7 (2005) 766-770
40. Bentwich I. A postulated role for microRNA in cellular differentiation. FASEB J 19 8 (2005) 875-879
41. Baskerville S., and Bartel D.P. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 11 (2005) 241-247
42. Shingara J., Keiger K., Shelton J., et al. An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA 11 (2005) 1461-1470
43. Sood P., Krek A., Zavolan M., et al. Cell type specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A 103 (2006) 2746-2751
44. Szafranska A.E., Davison T.S., John J., et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26 30 (2007) 4442-4452
45. Bloomston M., Frankel W.L., Petrocca F., et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297 17 (2007) 1901-1908
46. Deramaudt T., and Rustgi A.K. Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 1756 (2005) 97
47. Shi C., Hong S.M., Lim P., et al. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res 7 (2009) 230
48. Aguirre A.J., Bardeesy N., Sinha M., et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17 24 (2003) 3112-3126
49. Koch U., and Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci 64 (2007) 2746
50. Lomberk G., and Urrutia R. Primers on molecular pathways-notch. Pancreatology 8 (2008) 103
51. Miyamoto Y., Maitra A., Ghosh B., et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3 (2003) 565
52. Nielsen S.K., Mollgard K., Clement C.A., et al. Characterization of primary cilia and Hedgehog signaling during development of the human pancreas and in human pancreatic duct cancer cell lines. Dev Dyn 237 (2008) 2039
53. Thayer S.P., di Magliano M.P., Heiser P.W., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425 6960 (2003) 851-856
54. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (1801) 2008
55. Hald J., Hjorth J.P., German M.S., et al. Activated Notch1 prevents differentiation of pancreatic acinar cells and attenuate endocrine development. Dev Biol 260 2 (2003) 426-437
56. Murtaugh L.C., Stanger B.Z., Kwan K.M., et al. Notch signaling controls multiple steps of pancreatic differentiation. Proc Natl Acad Sci U S A 100 25 (2003) 14920-14925
57. Apelqvist A., Li H., Sommer L., et al. Notch signalling controls pancreatic cell differentiation. Nature 400 6747 (1999) 877-881
58. Fujikura J., Hosoda K., Kawaguchi Y., et al. Rbp-j regulates expansion of pancreatic epithelial cells and their differentiation into exocrine cells during mouse development. Dev Dyn 236 10 (2007) 2779-2791
59. Plentz R., Park J.S., Rhim A.D., et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 136 (2009) 1741
60. De La O.J., Emerson L.L., Goodman J.L., et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A 105 (2008) 18907
61. De La O.J., and Murtaugh L.C. Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling. Cell Cycle 8 (1860) 2009
62. Pasca di Magliano M., and Hebrok M. Hedgehog signaling in cancer formation and maintenance. Nat Rev Cancer 3 (2004) 903-911
63. Berman D.M., Karhadkar S.S., Maitra A., et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425 (2003) 846-851
64. Yauch R.L., Gould S.E., Scales S.J., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 455 7211 (2008) 406-410
65. + T cells. J Immunol 169 10 (2002) 5451-5457
66. Dennler S., Andre J., Alexaki I., et al. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 67 14 (2007) 6981-6986
67. Pasca di Magliano M., Sekine S., Ermilov A., et al. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 20 22 (2006) 3161-3173
68. Lowy A.M., Fenoglio-Preiser C., Kim O.J., et al. Dysregulation of beta-catenin expression correlates with tumor differentiation in pancreatic duct adenocarcinoma. Ann Surg Oncol 10 3 (2003) 284-290
69. Pasca di Magliano M., Biankin A.V., Heiser P.W., et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2 11 (2007) e1155
70. Wang L., Heidt D.G., Lee C.J., et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 15 3 (2009) 207-219
71. Rulifson I.C., Karnik S.K., Heiser P.W., et al. Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A 104 15 (2007) 6247-6252
72. Heiser P.W., Cano D.A., Landsman L., et al. Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology 135 4 (2008) 1288-1300
73. Lauth M., and Toftgard R. The Hedgehog pathway as a drug target in cancer therapy. Curr Opin Investig Drugs 8 6 (2007) 457-461
74. Shih Ie M., and Wang T.L. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 67 5 (2007) 1879-1882
75. Frese K.K., and Tuveson D.A. Maximizing mouse cancer models. Nat Rev Cancer 7 9 (2007) 645-658
76. Hezel A.F., Kimmelman A.C., Stanger B.Z., et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20 10 (2006) 1218-1249
77. Jackson E.L., Willis N., Mercer K., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15 24 (2001) 3243-3248
78. Kawaguchi Y., Cooper B., Gannon M., et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet 32 1 (2002) 128-134
79. Hingorani S.R., Petricoin E.F., Maitra A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 6 (2003) 437-450
80. Hingorani S.R., Wang L., Multani A.S., et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 5 (2005) 469-483
81. Bardeesy N., Aguirre A.J., Chu G.C., et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 103 15 (2006) 5947-5952
82. Siveke J.T., Einwachter H., Sipos B., et al. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12 3 (2007) 266-279
83. Bailey J.M., Mohr A.M., and Hollingsworth M.A. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene 28 (2009) 3513-3525
84. Nolan-Stevaux O., Lau J., Truitt M.L., et al. GLI1 is regulated through smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 23 1 (2009) 24-36
85. Olive K.P., Jacobetz M.A., Davidson C.J., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 5933 (2009) 1457-1461
86. Olive K.P., and Tuveson D.A. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 12 18 (2006) 5277-5287
87. Garcia-Faroldi G., Sanchez-Jimenez F., and Fajardo I. The polyamine and histamine metabolic interplay in cancer and chronic inflammation. Curr Opin Clin Nutr Metab Care 12 1 (2009) 59-65
88. McKay C.J., Glen P., and McMillan D.C. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol 22 1 (2008) 65-73
89. Jackson L., and Evers B.M. Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treat Res 130 (2006) 39-65
90. Guerra C., Schuhmacher A.J., Canamero M., et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-ras oncogenes in adult mice. Cancer Cell 11 3 (2007) 291-302
91. Clark C.E., Beatty G.L., and Vonderheide R.H. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett 279 1 (2009) 1-7
92. Wong S.B., Bos R., and Sherman L.A. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 180 5 (2008) 3122-3131
93. Clark C.E., Hingorani S.R., Mick R., et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67 19 (2007) 9518-9527
94. Hermann P.C., Huber S.L., Herrler T., et al. Distinct population s of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1 (2007) 313-323
95. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100 7 (2003) 3983-3988
96. Cammareri P., Lombardo Y., Francipane M.G., et al. Isolation and culture of colon cancer stem cells. Methods Cell Biol 86 (2008) 311-324
97. Chu P., Clanton D.J., Snipas T.S., et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 124 6 (2009) 1312-1321
98. Singh S.K., Clarke I.D., Hide T., et al. Cancer stem cells in nervous system tumors. Oncogene 23 43 (2004) 7267-7273
99. Zhang P., Zhang Y., Mao L., et al. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett 277 2 (2009) 227-234
100. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res 67 3 (2007) 1030-1037
101. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 7 (1997) 730-737